Targeting Human Cells with Modified VSV-G Protein
Author Information
Author(s): Dreja Hanna, Piechaczyk Marc
Primary Institution: Institut de Génétique Moléculaire de Montpellier, UMR 5535, IFR122, CNRS, France
Hypothesis
Can VSV-G be engineered to selectively deliver transgenes into human cells?
Conclusion
The study demonstrates that a modified VSV-G protein can specifically bind to human cells, but its ability to facilitate infection is significantly reduced.
Supporting Evidence
- The chimaeric VSV-G molecules can integrate into retroviral and lentiviral particles.
- HIV-1 particles pseudotyped with VSV-G linked to an scFv bind strongly to human cells.
- The modified protein shows inefficient fusion activity, leading to lower infection titres.
Takeaway
Scientists tried to change a virus protein so it could better target human cells, but it didn't work as well as they hoped.
Methodology
Chimaeric VSV-G proteins were constructed by linking a cell-directing single-chain antibody to its N-terminal and tested for binding and infection efficiency.
Limitations
The modified VSV-G showed poor fusogenicity and reduced viral particle titres compared to the native protein.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website